CTMX

CytomX Therapeutics (CTMX)

About CytomX Therapeutics (CTMX)

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Details

Daily high

$4.98

Daily low

$4.88

Price at open

$4.90

52 Week High

$6.35

52 Week Low

$0.40

Market cap

825.1M

Dividend yield

0.00%

Volume

127,291

Avg. volume

2.8M

P/E ratio

11.65

CytomX Therapeutics News